Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma.
Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma.
复制标题
上皮性卵巢癌患者的白细胞干扰素（IFN α）。
DOI：
--
复制
发表时间：
1983
期刊：
影响因子：
--
通讯作者：
Rutledge Fn
中科院分区：
文献类型：
--
作者：
R. S. Freedman;Gutterman Ju;Wharton Jt;Rutledge Fn
对15例卵巢上皮性癌患者化疗或放疗后给予人白细胞干扰素(IFN-α)治疗。观察到一种客观反应。3名患者的病情可能稳定长达6个月，其中2名患者在开始接受α干扰素治疗6个月后再次接受探查，1名患者的肿瘤直径缩小了不到50%。7名患者中有3名对随后的化疗有临床反应，表明对随后的化疗没有耐药性。毒性包括相对较轻的厌食、疲倦和腹泻症状。1例患者出现吸收不良。干扰素治疗后，血小板抑制和肝酶功能异常的发生率也更高。没有观察到危及生命的毒性。
Human leukocyte interferon (IFN alpha) was administered to 15 patients with epithelial ovarian carcinoma after previous chemotherapy or therapeutic irradiation. One objective response was observed. Three patients had possible stable disease for up to 6 months, including two patients who were re-explored 6 months after commencing IFN alpha and one patient who was observed to have a less than 50% reduction in her tumor diameters. Three of seven patients demonstrated clinical responses to subsequent chemotherapy, indicating an absence of resistance to subsequent chemotherapy. Toxicity included the relatively mild symptoms of anorexia, lassitude, and diarrhea. Malabsorption was observed in one patient. Platelet depression and abnormal enzyme liver functions were also observed more frequently following IFN alpha. No life-threatening toxicity was observed.